Simplified model of immunotherapy for glioblastoma multiforme: cancer stem cells hypothesis perspective
Clicks: 86
ID: 281543
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
25.5
/100
86 views
30 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #312 of 803 articles by views in arXiv
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 803 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Despite ongoing efforts in cancer research, a fully effective treatment for
glioblastoma multiforme (GBM) is still unknown. Since adoptive cell transfer
immunotherapy is one of the potential cure candidates, efforts have been made
to assess its effectiveness using mathematical modeling. In this paper, we
consider a model of GBM immunotherapy proposed by Abernathy and Burke (2016),
which also takes into account the dynamics of cancer stem cells, i.e., the type
of cancer cells that are hypothesized to be largely responsible for cancer
recurrence. We modify the initial ODE system by applying simplifying
assumptions and analyze the existence and stability of steady states of the
obtained simplified model depending on the treatment levels.
| Reference Key |
foryś2025simplified
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Wiktor Jochymczyk; Urszula Foryś |
| Journal | arXiv |
| Year | 2025 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.